Bone is a living metabolic organ. It is constantly being broken down by osteoclasts and rebuilt by osteoblasts in a tightly regulated cycle governed by calcium, phosphate, parathyroid hormone, vitamin D, and a network of hormonal and cellular signals. When this cycle is disrupted, the result is a spectrum of disorders that range from the extremely common, such as osteoporosis, to the ultra-rare, such as hypophosphataemia caused by FGF23 excess. For international patients considering India for advanced diagnosis and treatment, understanding what these disorders are, which investigations clarify them, and which treatments are now available is the starting point. India's leading endocrinology and metabolic bone disease centres at NABH-accredited hospitals offer the full diagnostic and therapeutic spectrum at 60 to 80 percent lower cost than Western equivalents.
What Are the Disorders of Bone and Mineral Metabolism?
Disorders of bone and mineral metabolism arise from abnormalities in any of the key regulators of skeletal homeostasis: calcium, phosphate, parathyroid hormone (PTH), vitamin D, magnesium, or the downstream cellular signals that govern bone formation and resorption. They are most usefully grouped into four categories:
Category 1: Disorders of Calcium Regulation
These conditions involve too much or too little calcium in the blood, usually driven by abnormal parathyroid gland function or vitamin D metabolism.
-
Primary hyperparathyroidism: Excessive PTH secretion from one or more abnormal parathyroid glands raises serum calcium, depletes bone density, and in symptomatic or severe cases causes kidney stones, bone pain, and fractures. It is the most common cause of hypercalcaemia in outpatients and is corrected by surgical parathyroidectomy. Minimally invasive parathyroidectomy guided by pre-operative sestamibi scan and intraoperative PTH monitoring is available at India's leading endocrine surgery centres.
-
Hypoparathyroidism: Insufficient PTH causes hypocalcaemia, producing numbness, tetany, and in severe cases seizures. Most commonly occurs after thyroid or parathyroid surgery. Long-term management uses calcium and active vitamin D supplements. Recombinant PTH (rhPTH 1-84, Natpara) is available at India's academic endocrinology centres for patients who cannot be adequately controlled with conventional supplementation.
-
Familial hypocalciuric hypercalcaemia (FHH): A benign inherited condition caused by inactivating mutations in the calcium-sensing receptor (CaSR), producing mild hypercalcaemia that does not require treatment. Distinguishing FHH from primary hyperparathyroidism is clinically critical because FHH does not benefit from parathyroidectomy.
Category 2: Disorders of Phosphate Regulation
Phosphate disorders are less commonly recognised than calcium disorders but are responsible for significant bone disease.
-
X-linked hypophosphataemia (XLH): The most common hereditary phosphate-wasting disorder, caused by FGF23 excess that prevents phosphate reabsorption in the kidney. It produces rickets in children and osteomalacia with fractures and pain in adults. Burosumab, a monoclonal antibody against FGF23 approved by the FDA and EMA, is now available in India and represents the first targeted therapy for XLH. It produces significantly better mineralisation and phosphate levels than conventional phosphate and active vitamin D supplementation.
-
Tumour-induced osteomalacia (TIO): A rare paraneoplastic syndrome where a phosphaturic tumour secretes excess FGF23, causing severe bone pain, stress fractures, and muscle weakness. The tumour is often tiny and requires gallium-68 DOTATATE PET/CT for localisation. Surgical resection is curative. TIO is frequently misdiagnosed for years as fibromyalgia or degenerative spine disease before the phosphate disorder is identified.
-
Hypophosphataemia from chronic kidney disease: Impaired phosphate excretion in CKD leads to hyperphosphataemia, secondary hyperparathyroidism, and renal osteodystrophy, a complex bone disease requiring phosphate binders, active vitamin D analogues, and calcimimetics.
Category 3: Metabolic Bone Diseases
These are structural disorders of bone quality arising from deficient mineralisation, abnormal bone turnover, or genetic defects in bone-forming proteins.
- Osteoporosis: The most prevalent disorder of bone and mineral metabolism globally, affecting an estimated 500 million people. Defined by reduced bone mineral density and impaired bone quality, resulting in fragility fractures of the hip, spine, and wrist. Treatment is highly individualised and has expanded significantly:
| Agent class | Examples | Mechanism | Indication |
|---|---|---|---|
| Bisphosphonates | Alendronate, zoledronic acid | Inhibit osteoclast activity | First-line for most patients |
| Denosumab | Prolia | RANKL inhibitor, antiresorptive | Alternative to bisphosphonates, renal impairment |
| Romosozumab | Evenity | Sclerostin inhibitor, anabolic + antiresorptive | High fracture risk, treatment-naive severe OA |
| Teriparatide / abaloparatide | Forteo / Tymlos | PTH analogue, anabolic | Very high fracture risk, failed antiresorptives |
Romosozumab, the newest anabolic-antiresorptive agent approved for severe osteoporosis, is available at India's leading metabolic bone disease centres. Sequential therapy from anabolic to antiresorptive is now standard for the highest-risk patients.
-
Osteomalacia and rickets: Defective bone mineralisation from vitamin D deficiency, phosphate wasting, or enzyme deficiencies (alkaline phosphatase in hypophosphatasia). Vitamin D deficiency-related osteomalacia responds to cholecalciferol supplementation and calcium. Hypophosphatasia, caused by loss-of-function mutations in ALPL, is treated with asfotase alfa, an enzyme replacement approved for paediatric and adult hypophosphatasia.
-
Paget's disease of bone: Focal accelerated bone turnover producing expanded, deformed, and architecturally weak bone, most commonly in the pelvis, skull, spine, and femur. Bisphosphonates, particularly intravenous zoledronic acid, suppress Paget's activity effectively and are available in India as generic formulations at a fraction of Western costs.
Category 4: Rare Skeletal Dysplasias and Genetic Bone Disorders
Several genetic conditions produce skeletal abnormalities through bone-intrinsic mechanisms:
-
Osteogenesis imperfecta (OI): Caused by mutations in collagen type I genes, producing brittle bones, multiple fractures, and blue sclerae. Bisphosphonate infusion cycles (pamidronate or zoledronic acid) reduce fracture frequency significantly. Surgical rodding of long bones stabilises limbs in moderate to severe OI.
-
Fibrous dysplasia: Replacement of normal bone by fibrous tissue driven by GNAS mutations. Bisphosphonates reduce bone pain and stabilise lesions. Surgical deformity correction is indicated for weight-bearing bone deformity.
-
Cleidocranial dysplasia, achondroplasia, and multiple hereditary exostoses each produce specific radiological and clinical patterns requiring genetic confirmation and subspecialty orthopaedic management.
How These Disorders Are Diagnosed in India
A complete metabolic bone workup at India's leading endocrinology centres includes the following, typically completed within one to two days of arrival:
-
Serum calcium, phosphate, magnesium, alkaline phosphatase
-
PTH (intact), PTHrP where TIO is suspected
-
25-hydroxyvitamin D and 1,25-dihydroxyvitamin D
-
24-hour urine calcium and phosphate
-
FGF23 (fibroblast growth factor 23) for phosphate wasting disorders
-
Bone density by DEXA scan
-
Vertebral fracture assessment
-
Genetic panel for hereditary bone disorders where indicated
-
68Ga-DOTATATE PET/CT for TIO localisation
Why International Patients Choose India for Metabolic Bone Disease Treatment
India's endocrinology and metabolic bone disease centres offer the full treatment spectrum at costs that reflect the healthcare economics of a country with different pricing structures but equivalent clinical standards at accredited institutions. Key treatments available in India at significantly lower cost than Western countries:
-
Zoledronic acid infusion for osteoporosis and Paget's disease: available as generic at approximately Rs. 1,500 to Rs. 3,000 (USD 18 to USD 36) versus USD 1,000 to USD 3,000 in the USA
-
Denosumab injections: available in India at Rs. 6,000 to Rs. 12,000 (USD 72 to USD 145) per six-monthly injection versus USD 800 to USD 1,200 in the USA
-
Romosozumab: available at India's academic centres at Rs. 20,000 to Rs. 40,000 per monthly injection (USD 240 to USD 480) versus USD 2,000 per injection in the USA
-
Burosumab for XLH: available at India's rare disease centres with pricing substantially below Western market rates
-
Asfotase alfa for hypophosphatasia: available through compassionate use and specialist programmes
DEXA bone density scanning costs Rs. 1,500 to Rs. 3,500 (USD 18 to USD 42) in India versus USD 150 to USD 300 in the USA. 68Ga-DOTATATE PET/CT for TIO localisation costs Rs. 25,000 to Rs. 40,000 (USD 300 to USD 480) versus USD 3,000 to USD 6,000 in the USA.
Karetrip reviews each patient's existing investigation results and clinical summary before recommending the most appropriate metabolic bone disease specialist in India, ensuring that the diagnosis is confirmed before treatment begins and that the proposed treatment is appropriate for the specific disorder.
How Karetrip Supports International Patients
Karetrip reviews each patient's existing blood results, bone density reports, and clinical history before recommending a metabolic bone disease specialist, ensuring the diagnostic workup is targeted and the treatment plan matches the specific disorder. From medical visa coordination through accommodation and discharge planning for ongoing treatment continuation at home, Karetrip manages the complete journey.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward expert metabolic bone disease diagnosis and treatment in India.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Bone and mineral metabolism disorders require evaluation by a qualified endocrinologist or metabolic bone disease specialist.